Physician profile
Mitchell Finnie
NPI 1245236231
$14,659.44
in general payments reported to CMS, 2019-2025
59 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $2,078 · 2021: $2,561 · 2022: $2,490 · 2023: $2,175 · 2024: $1,560 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,294 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,293.56 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,756.10 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,590.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,051.24 | 2019-2025 | |
| Lilly USA, LLC | $975.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $709.31 | 2019-2025 | Breztri, Farxiga |
| Allergan, INC. | $665.25 | 2019-2020 | |
| Amarin Pharma, INC. | $578.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.47 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $545.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $522.22 | 2019-2024 | Belsomra, Steglujan, Gardasil 9 |
| Glaxosmithkline, LLC. | $510.63 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $447.17 | 2019-2025 | |
| Esperion Therapeutics, INC. | $333.97 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $301.44 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $281.30 | 2021-2025 | Nuzyra |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Finnie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.